1Bourouba M, Benyelles-Boufennara A, Terki N, et al. Epidermal growth factor receptor(EGFR) abundance cor- relates with p53 and Bcl-2 accumulation and patient age in a small cohort of north african nasopharyngeal carcino- ma patients [ J ]. Eur Cytokine Netw, 2011,22 ( 1 ) : 38- 44.
2Hwangbo W, Lee J H, Ahn S, et al. EGFR. Gene ampli- fication and protein expression in invasive ductal carcino- ma of the breast[ J ]. Korean J Pathol, 2013,47 (2) : 107- 115.
3Corcoran R B, Conlino G, Deshpande V, et al. STAT3 plays a critical role in k-ras-induced pancreatic tumori- genesis [ J ]. Cancer Res, 2011,71 (14) :5020-5029.
4Morris J P, Cano D A, Sekine S, et al. ~-catenin blocks k-ras-dependent reprogramming of acini into pancreatic cancer precursor lesions in mice[ J]. J Clin Invest, 2010, 120 ( 2 ) :508-520.
5Watanabe T, Kobunai T, Yamamoto Y, et al. Gene ex-pression signature and response to the use of leucovorin, fluorouracil and oxaliplatin in colorectal cancer patients [J~. Clin Transl Oncol, 2011,13(6) :419425.
6Hubert T, Vandekerckhove J, Gettemans J, et al. Cdkl and BRCA1 target ~-tubulin to microtubule domains[ J ]. Biochem Bio-phys Res Commun, 2011 , 414 ( 1 ) : 240- 245.
7Wolff A C, Hammond M E, Hicks D G, et al. Recom- mendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical On- cology/College of American guideline update ~ ] ~. Arch (2) :241-256.
8Pathologists clinical practice Pathol Lab Med, 2014,138 Ineorvati :l A, Shah S, Mu Y, et al. Targeted therapy for HER2 positive breast cancer [ J 1. J Hematol Oncol, 2013,6:38.
9Dieras V, Bachelot T. The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breastcancer[J]. Target Oncol, 2014,9(2) :111-122.
10Ren J, Li G, Ge J, et al. Is K-ras gene mutation a prog- nostic factor for colorectal cancer: a systematic review and Rectum, 2012,55 (8) :913-.
